•  
  •  
 

Abstract

Objectives: to assess the effectiveness of systemic immune-inflammation index (SII), red blood cell distribution width (RDW), and their combination in predicting Hepatocellular carcinoma (HCC) patient survival. Background: HCC is among the most prevalent cancers and the third leading cause of cancer-related deaths worldwide. The SII and RDW are markers of chronic inflammation calculable from a complete blood count (CBC). Methods: an observational prospective study conducted on 60 newly diagnosed HCC patients. Patients were followed every 3 months for a year, with clinical, laboratory (SII and RDW), data recorded at baseline, 3, 6, and 9 months. Results: In this study, we compared the demographic and clinical characteristics between HCC patients who were alive and those who had died. Males were predominant in both groups (72.7% alive vs. 88.9% dead), and the mean age was slightly higher in the dead group (63.11 ± 6.81 years vs. 61.78 ± 6.08 years). A significant difference was noted on the receipt of direct-acting antiviral agents (DAAs), with 93.9% of the alive group receiving DAAs compared to 66.7% of the dead group (P=0.007). Additionally, SII and RDW-CV showed a significant increase in the dead group at 3, 6, 9 months indicating their potential as prognostic markers Conclusions: HCC patients with elevated SII and RDW values are associated with poor overall survival compared to those with lower values.

Subject Area

Internal Medicine

Article Type

Original Study

Download

Share

COinS